Inhaled bacteria protein could train lungs to fight pneumonia
NCT ID NCT06681402
First seen Apr 19, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-stage trial tested a single inhaled dose of FLAMOD, a protein from bacteria, in 46 healthy adults. The goal was to see if it is safe and can activate the immune system in the lungs. Researchers are looking for the best dose that triggers immune responses without causing serious side effects. This is a first step toward possibly preventing pneumonia in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre hospitalier régional universitaire de de Tours
Tours, 37044, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FLAMOD (flagellin, a protein from bacteria)
What this could lead to
If successful, this could point toward a new way to boost lung immunity and prevent pneumonia.
What could go wrong
This is a very early Phase 1 safety trial in only 46 healthy people. It does not test whether FLAMOD actually prevents pneumonia, and results may not apply to sick patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.